The present invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the present invention is directed to compounds of Formula I, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are defined herein. It is as it is done. The compounds of the invention are inhibitors of PERK and are associated with activated unfolding protein response pathways, cancers, precancerous syndromes and diseases / injuries such as Alzheimer''s disease, neuropathic pain, spinal cord injury, traumatic Brain injury, ischemic stroke, stroke, Parkinson''s disease, diabetes, metabolic syndrome, metabolic disorders, Huntington''s disease, Creutzfeldt-Jakob disease, lethal familial insomnia, Gerstman-Streisler-Scheinker syndrome and related prion diseases, muscle Amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, heart disease, inflammation, organ fibrosis, chronic and acute liver disease, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute lung disease, lung Fibrosis, chronic and acute kidney disease, renal fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, frontotemporal dementia, tauopa Chromatography, Pick''s disease, Niemann-Pick disease, amyloidosis, cognitive disorders, atherosclerosis, may be useful in the treatment of ophthalmic diseases, arrhythmia, organ transplantation and during transportation of organs for transplantation. Thus, the present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention. The present invention is still further directed to methods of inhibiting PERK activity using the compounds of the present invention or pharmaceutical compositions comprising the compounds of the present invention and the treatment of disorders associated therewith.本発明は、置換ピロリジノンおよびイミダゾリジノン誘導体を対象とする。具体的には、本発明は、式Ｉの化合物を対象とし、式中、Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、Ｒ６、Ｒ７、ＸおよびＹは本明細書に定義される通りである。本発明の化合物はＰＥＲＫの阻害剤であり、活性化されたアンフォールディングタンパク質応答経
